Joel Neal, MD, PhD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Merck
    Topic:
    research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Boehringer Ingelheim
    Topic:
    research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Nektar Therapeutics
    Topic:
    research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Adaptimmune
    Topic:
    research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    GSK
    Topic:
    research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Janssen
    Topic:
    research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    CME Matters, Clinical Care Options CME, Research to Practice CME, Medscape CME, Biomedical Learning Institute CME, MLI Peerview CME, Prime Oncology CME, Projects in Knowledge CME, Rockpointe CME, MJH Life Sciences CME, Medical Educator Consortium, HMP Edu
    Topic:
    honoraria
    Date added:
    06/13/2023
    Date updated:
    03/14/2024

Pages

Return to 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes